secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000939767-23-000047
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q1 revenue up 15% to $408.8M, but GAAP EPS falls to $0.12 on higher R&D spend
--------------------------------------------------------------------------------

- Total revenues $408.8M (+15% YoY); Cabozantinib franchise net product revenues $363.4M (+17% YoY).
- GAAP net income $40.0M ($0.12 diluted EPS) vs $68.6M ($0.21) YoY; non-GAAP diluted EPS $0.16 vs $0.26.
- R&D expense rose to $234.2M from $156.7M YoY, driven by license costs and pipeline manufacturing.
- Announced $550M share repurchase program to be executed by end of 2023; reaffirms long-term confidence.
- Pipeline advances: STELLAR-303 and -304 Phase 3 trials for zanzalintinib, XB002 Phase 1 dose escalation ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000047/0000939767-23-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000047/exel-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000939767-23-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer